Corvus Shareholders Must Be Happy With This COVID-19 Study Update
Corvus Pharmaceuticals shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.
Corvus Pharmaceuticals shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.
MyoKardia shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb would be acquiring the company.
These five high-conviction medical technology health care ideas from Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well during the fourth quarter, into 2021…
As COVID-19 begins to spread in New York City for a second time this year, hotspots have developed in over a dozen ZIP codes.
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Compared to the office and retail real estate investment trusts, which have been hit hard during the pandemic, the medical office REITs have held up extremely well, and investors are starting to notice.
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and…
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.
Almost 6 million Americans 65 and older are living with Alzheimer’s disease. In one state, the number is expected to increase by a third in the next five years.
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH | LH Price Prediction). This agreement is ultimately for Genfit’s technology to…
Eiger BioPharmaceuticals has announced disappointing results from a study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.